Drug Trial Radar · NCT06526819
SMP-3124LP in Adults With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Aug 14, 2024
Primary completion
Dec 2028
Study completion May 2029
Sponsor
- Lead sponsor
- Sumitomo Pharma America, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
Conditions
- Solid Tumor
Interventions
SMP3124LPDrug
Liposomal encapsulation formulation of SMP-3124
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determination of the Recommended Phase 2 Dose by Assessing Dose-limiting Toxicities (DLTs)Time frame: 28 days
- Number of Participants With Adverse Events and Serious Adverse EventsTime frame: 6 months
- Determine the Objective Response Rate (ORR)Time frame: 6 months
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Cedars Sinai Medical Center
Los Angeles, California · Recruiting
University of California, San Francisco
San Francisco, California · Not yet recruiting
Sarah Cannon Research Institute at HealthOne
Denver, Colorado · Recruiting
Advent Health
Celebration, Florida · Recruiting
Northwestern Medicine Cancer Center
Chicago, Illinois · Recruiting
The University of Chicago
Chicago, Illinois · Recruiting
Ohio State University
Columbus, Ohio · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Washington
Seattle, Washington · Recruiting
National Cancer Center Hospital East
Kashiwa-shi, Japan · Recruiting
Kyoto University Hospital
Kyoto, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.